BioStock: Saniona’s CEO comments on the billion dollar deal
Saniona has entered into an exclusive global licensing agreement with Jazz Pharmaceuticals for the development and commercialization of SAN2355, a preclinical asset targeting epilepsy and other potential indications. The deal carries a total potential value of over 1 billion USD, including USD 42.5 million upfront, milestone payments, and royalties. We turned to CEO Thomas Feldthus for a comment on this milestone and what it means for Saniona’s future.
Read the full interview at biostock. se:
https://biostock.se/en/2025/08/sanionas-ceo-comments-on-the-billion-dollar-deal/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/